EUVIMEDEUVIMED entdecken
Fallbericht

A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience

Fangfang Cao, Jihua Xie, Zhixin Huang, Ling Xiong, Jian Zha iD

International Journal of Developmental Neuroscience · 2026-06 · 86 (4)

DOI: 10.1002/jdn.70148 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Developmental Neuroscience, online erschienen am 12.06.2026. Verfasst von Fangfang Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, China. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Repressor Proteins, Neurodevelopmental Disorders, Frameshift Mutation. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurodevelopmental disorders were a wide range of cognitive and behavioural disorders. Its pathogenic genes, transduction beta like 1 X‐linked receptor 1 ( TBL1XR1 ), had been a hot research topic recently. However, reports involving treatment and long‐term follow‐up were still limited.

Methods

Exome sequencing of the family was performed. The clinical data and genetic variants, treatment and long‐term follow‐up were summarized. Moreover, treatment of published cases was also summarized to systematically understand its treatment strategies.

Results

Genetic screening revealed a de novo variant of TBL1XR1 [NM_024665.7: c.1372_1387dup, p.Asp463Glyfs*6]. The variant was a 16‐bp nucleotide duplication in exon 14, caused a conversion of the aspartic amino acids to glycine amino acids at the 463rd and finally generated a stop codon 6 amino acids after the 462nd amino acids. It was classified as a variant of pathogenic (P) according to the ACMG (American College of Medical Genetics and Genomics) guidelines. Valproic acid was administered up to 20 mg/kg/day, which resulted in satisfactory seizure control. Long‐term follow‐up confirmed the complete disappearance of seizures at 5 and 6 months of age, although hyperactivity, attention deficit and global developmental delay persisted.

Conclusion

Our results expanded the pathogenic variant spectrum and treatment of TBL1XR1 ‐related neurodevelopmental disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Cytoplasmic and NuclearRepressor ProteinsNeurodevelopmental DisordersFrameshift MutationNuclear ProteinsHumansMaleFemaleValproic AcidChildAnticonvulsants

Stichwörter der Autor:innen

TBL1XR1ACMGepilepsyneurodevelopmentalvalproic acid

Substanzen

TBL1XR1 protein, humanReceptors, Cytoplasmic and NuclearRepressor ProteinsNuclear ProteinsValproic AcidAnticonvulsants

Autor:innen und Institutionen

  • Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, China.

ORCID-Profile: Jian Zha

Zitieren

APA

Cao, F., Xie, J., Huang, Z., Xiong, L., & Zha, J. (2026). A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience. International Journal of Developmental Neuroscience, 86(4). https://doi.org/10.1002/jdn.70148

Vancouver

Cao F, Xie J, Huang Z, Xiong L, Zha J. A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience. International Journal of Developmental Neuroscience. 2026;86(4). doi:10.1002/jdn.70148

BibTeX
@article{Cao2026,
  author = {Cao, Fangfang and Xie, Jihua and Huang, Zhixin and Xiong, Ling and Zha, Jian},
  title = {A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience},
  journal = {International Journal of Developmental Neuroscience},
  year = {2026},
  volume = {86},
  number = {4},
  doi = {10.1002/jdn.70148}
}
Kostenlos starten →